原發(fā)性肝癌（primary liver cancer,PLC）的高發(fā)性與高致死性,嚴(yán)重危害了我國(guó)人民的生命健康。經(jīng)導(dǎo)管肝動(dòng)脈灌注化療栓塞（transcatheter arterial chemoembolization,TACE）是非手術(shù)治療中晚期PLC首選方法。TACE術(shù)后最常見(jiàn)并發(fā)癥是急性肝損傷（acute liver injury,ALI）,嚴(yán)重肝損傷患者會(huì)出現(xiàn)黃疸、腹水、肝性腦病,甚至急性肝功能衰竭等導(dǎo)致治療相關(guān)性死亡。如何減少TACE所致ALI,進(jìn)一步改善患者的生活質(zhì)量并延長(zhǎng)生存期,一直是臨床上治療中晚期PLC的熱點(diǎn)和難點(diǎn)問(wèn)題。TACE包括肝動(dòng)脈灌注化療和栓塞,造成ALI的主要原因?yàn)?（1）動(dòng)脈灌注化療藥物所致藥物性肝損傷（drug-induced liver injury,DILI）,研究顯示化療藥物及藥物在代謝過(guò)程中所產(chǎn)生的親電子產(chǎn)物,可促使線粒體產(chǎn)生大量活性氧自由基（reactive oxygen species,ROS）,造成氧化應(yīng)激性肝損傷。（2）栓塞劑所致肝損傷,TACE術(shù)中常因腫瘤供養(yǎng)血管扭曲、打折導(dǎo)致難以完成超選擇性灌注化療栓塞（superselective ... 

【文章來(lái)源】：河北醫(yī)科大學(xué)河北省

【文章頁(yè)數(shù)】：155 頁(yè)

【學(xué)位級(jí)別】：博士

【部分圖文】：

小鼠肝臟組織切片的H&E染色及組織損傷評(píng)分比較（x±s）

圖 2 小鼠心臟組織切片的 H&E 染色及組織損傷評(píng)分比較（x±s）ig.2 Comparison of H&E staining and the injury scores of heart histologice ( x ±s).Note: The heart tissue showed structural integrity in the norntrol group (Control). The cardiomyocytes showed disordered arrangemstructive structure, some degeneration and necrosis in the DOX grlack arrow). The myocardial cells returned to normal in the Me-treatment groups, almost with no difference compared with normal conoup. L-MgIG group included rare slightly swollen cells (black arrow). ale bar represented 50 μm (original magnification, 400×). The cartogramrdiac tissue injury scores showed: **P＜0.01 vs DOX group;##P＜0.01ontrol group; Comparison among the intervention groups (L-MgIG gro-MgIG group, H-MgIG group) , P＜0.01.

圖 3 Bax、Bcl-2 蛋白在小鼠肝臟組織中的表達(dá)（x±s）Fig.3 Expression of Bax and Bcl-2 protein in liver tissue of mice (x±s)ote:1. Normal control group (Comtrol), 2. L-MgIG group, 3. M-MgIG gr. H-MgIG group, 5. DOX group. There is a certain amount of Bax, Botein expression in the liver tissue of the normal control group. Compith normal control group, the expression of Bax protein significahanced and the expression of Bcl-2 was significantly decreased in Doup. Compared with DOX group, intervention group significantly decrepression of Bax protein and increased the expression of Bcl-2 protein ncentration dependent manner. Cartogram representation: **P ＜ 0.01OX group;##P＜0.01 vs Control group; Comparison among the intervenoups (L-MgIG group, M-MgIG group, H-MgIG group) , P＜0.01.

【參考文獻(xiàn)】：
期刊論文
[1]原發(fā)性肝癌經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞術(shù)后應(yīng)用不同保肝方案的效果比較研究[J]. 武中林,吳勇超,楊超,吳建華,李順宗,楊光,李智崗.  中國(guó)全科醫(yī)學(xué). 2017(23)
[2]原發(fā)性肝癌診療規(guī)范（2017年版）[J]. National Health and Family Planning Commission of the People’s Republic of China;.  臨床肝膽病雜志. 2017(08)
[3]原發(fā)性肝癌的抗血管生成靶向治療現(xiàn)狀與挑戰(zhàn)[J]. 陳丹,王凱冰,李加樁,隋紅.  中國(guó)腫瘤. 2017(03)
[4]18β-甘草次酸對(duì)肝癌HepG2細(xì)胞增殖及PI3K、PDK1、AKT蛋白表達(dá)的影響[J]. 金鑫,李慧,李剛,趙海燕.  山東醫(yī)藥. 2017(03)
[5]河北省肝癌發(fā)病和死亡40年變化趨勢(shì)分析[J]. 師金,李道娟,梁迪,靳晶,溫登瑰,賀宇彤.  腫瘤防治研究. 2016(11)
[6]肝臟缺血再灌注損傷中線粒體膜氧化應(yīng)激和電生理功能障礙的分子機(jī)制研究[J]. 金濤,王興強(qiáng),劉超.  天津醫(yī)藥. 2016(11)
[7]中藥單體治療原發(fā)性肝癌實(shí)驗(yàn)研究進(jìn)展[J]. 張少鵬,姚樹(shù)坤,宋威江,李蕊.  中日友好醫(yī)院學(xué)報(bào). 2016(05)
[8]肝動(dòng)脈化療栓塞術(shù)（TACE）對(duì)原發(fā)性肝癌患者的肝功能影響及相關(guān)因素分析[J]. 賀愛(ài)軍,任羽,姬樂(lè),吳耀祿.  中國(guó)實(shí)驗(yàn)診斷學(xué). 2016(09)
[9]肝癌綜合介入治療研究進(jìn)展[J]. 杜松,郭應(yīng)興.  現(xiàn)代臨床醫(yī)學(xué). 2016(05)
[10]TACE治療原發(fā)性肝癌對(duì)肝功能的影響及相關(guān)因素的研究[J]. 王甦,黃一楓,劉佳,周年蘭.  胃腸病學(xué)和肝病學(xué)雜志. 2016(08)



本文編號(hào)：3363482